US 12,679,833 · Application 18/007,641 · Granted Jul 14, 2026
US 12,679,833
N-cyanopyrrolidines with activity as usp30 inhibitors
Estimated expiration
April 11, 2043
16y 217d remaining
- Could not fetch continuity data for application PCTEP2021064897: Resource not found (404)
Earliest effective filing
Jun 3, 2021
+ 20 years
Jun 3, 2041
PTA +677d
Apr 11, 2043
No TD
—
Final
Apr 11, 2043
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- December 1, 2022
- Earliest effective filing
- June 3, 2021
- Issue date
- July 14, 2026
- PTA
- +677 days
- Base expiry (before PTA)
- June 3, 2041
June 3, 2021 + 20 years = June 3, 2041 + 677 PTA days = April 11, 2043
- National stage entry of application PCTEP2021064897, filed Jun 3, 2021
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 18/007,641 · US 12,679,833
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,679,833: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12679833Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.